It was previously PR-ed that Mellow Hope generates over $15 Million in Revenues:
Mellow Hope revenues are currently in excess of $15 million USD, and growing and now it will be much higher i guess...
To be on the safe side, let’s presume that the HTDS Outstanding Shares (OS) amount is maxed out to be what their AS is (5 Billion Shares) to derive a valuation.
Let’s figure a conservative 25% Net Profit Margin from the over $15 million in Revenues that is generated by their subsidiary, Mellow Hope.
Now consider the derived Earnings Per Share (EPS) below:
OS = 5,000,000,000 Shares
Net Income = 25% x $15,000,000 = $3,750,000
Net Income ÷ OS = EPS
$3,750,000 ÷ 5,000,000,000 OS Shares = EPS
.00075 = EPS
PE Ratio x EPS = Fundamental Share Price Valuation
12 Conservative PE Ratio x .00075 = Fundamental Share Price Valuation
.009 per share = Fundamental Share Price Valuation
>>>>>>So real Value shoud be around 0.009 to 0.01<<<<<<<<<
Since the acquisition has been completed, this is not a speculative number. This number leans more towards being an “actual” valuation based on the acquisition of Mellow Hope being completed and based on Mellow Hope generating over $15 million in Revenues. This valuation also does not include any Revenues generated from their other subsidiary or from the agreement that Mellow Hope has done with Yunnan
Walvax Biotech. This valuation also does not include any value that could come from their recent news if they recover 100% intellectual property (IP) rights that could provide an enormous financial benefit to the company so the valuation could very well be much higher. Their agreement with Yunnan Walvax Biotech Co., Ltd on the issue of Haemophilus influenza type "B" conjugate vaccine will significantly
add to the already over $15 million in Revenues:
Yunnan Walvax Biotech Co., Ltd is the second biggest manufacturer of Haemophilus influenza type b conjugate vaccine in China.
>>>>>>>>> Now Add this from their recent PR<<<<<<<<<<<<<<<
The IP rights are being utilized by a fully reporting OTCBB publicly traded company. As a result of HTDS IP rights, this company has raised over $14 million in equity financing, constructed an operating plant that generates revenue, is in the process of purchasing parcels of property in various States in order to construct additional plants and has had numerous industrial bonds approved for an average amount of
$10 million each.
Once the rights have been reasserted by HTDS, various projections (based on confidential financial documents and projections of the OTCBB company) indicates gross revenue exceeding $250 million, gross profit exceeding $220 million and net income exceeding $40 million within two years.
Now any one can guess what will be in next Q2 and what will be the price prediction after their Q2 ??
Message wrote by: keithkeith
